Specific recommendations for implantation of each prosthesis , taking into consideration the presence of pre-existent conduction abnormalities and anatomical factors , may be needed to reduce the risk of PPI
Aims The incidence of new-onset conduction abnormalities requiring permanent pacemaker implantation ( PPI ) after transcatheter aortic valve implantation ( TAVI ) with new-generation prostheses remains debated .
This systematic review analyses the incidence of PPI after TAVI  with new-generation devices and evaluates the electrical , anatomical , and procedural factors associated with PPI .
In addition , the incidence of PPI after  TAVI with early generation prostheses was review ed for comparison .
Implantation and 30-Day Follow-Up on All 4 Valve Sizes Within the Portico Transcatheter Aortic Bioprosthetic Family.
OBJECTIVES The aim of this study was to evaluate the short-term safety and performance of the full range of valve sizes offered within the Portico transcatheter aortic valve replacement system . BACKGROUND The Portico transcatheter aortic heart valve is a fully resheathable , repositionable , and self-exp and ing bioprosthesis design ed to achieve optimal valve position and hemodynamic performance and limit conduction disturbances . METHODS Patients ( n = 222 ) with symptomatic ( New York Heart Association functional class ≥II ) severe aortic stenosis considered by a multidisciplinary heart team to be at high surgical risk were recruited between December 2011 and September 2015 in this prospect i ve , nonr and omized , multicenter study . Patients were implanted with the full range of Portico heart valves  ( 23 , 25 , 27 , and 29 mm ) using the transfemoral approach . The primary endpoint was all-cause mortality at 30 days . Secondary endpoints included valve performance , improvement in functional class , and procedural outcomes as defined by Valve Academic Research Consortium criteria . RESULTS A total of 220 patients ( mean age 83.0 ± 4.6 years , 74.3 % women , mean Society of Thoracic Surgeons score 5.8 % ) had valves implanted . All resheathing and repositioning attempts ( n = 72 ) were successful . At 30 days , all-cause mortality was 3.6 % . Procedural outcomes included disabling ( major ) stroke ( 3.2 % ) , major vascular complications ( 7.2 % ) , and permanent pacemaker implantation ( 13.5 % ) . Compared with baseline , 75.8 % of patients improved by ≥1 New York Heart Association functional class at 30 days . The rate of moderate paravalvular leak was 5.7 % , with no severe paravalvular leak reported . No differences in paravalvular leak incidence and severity were observed among valve sizes ( p = 0.24 ) . CONCLUSIONS Across all valve sizes , use of the repositionable Portico transcatheter aortic valve replacement system result ed in safe and effective treatment of aortic stenosis in high-risk patients
Specific recommendations for implantation of each prosthesis , taking into consideration the presence of pre-existent conduction abnormalities and anatomical factors , may be needed to reduce the risk of PPI
Aims The incidence of new-onset conduction abnormalities requiring permanent pacemaker implantation ( PPI ) after transcatheter aortic valve implantation ( TAVI ) with new-generation prostheses remains debated .
This systematic review analyses the incidence of PPI after TAVI  with new-generation devices and evaluates the electrical , anatomical , and procedural factors associated with PPI .
In addition , the incidence of PPI after  TAVI with early generation prostheses was review ed for comparison .